Breaking News

European Court Orders Russia to Pay €1.87 Billion for Yukos Seizure
Tweet TWEET

Marina Biotech Announces Worldwide Non-Exclusive Licensing

Marina Biotech Announces Worldwide Non-Exclusive Licensing Agreement
for Nucleic Acid Chemistry to Tekmira Pharmaceuticals 
BOTHELL, WA -- (Marketwire) -- 11/29/12 --  Marina Biotech, Inc.
(PINKSHEETS: MRNA), a leading oligonucleotide-based drug discovery
and development company, announced today that it has entered into a
license agreement with Tekmira Pharmaceuticals Corporation (NASDAQ:
TKMR) (TSX: TKM), where Marina will provide Tekmira a worldwide,
non-exclusive license to Marina Biotech's Unlocked Nucleobase Analog
(UNA) technology for the development of RNA interference
therapeutics. Tekmira will have full responsibility for the
development and commercialization of any products arising under the
Agreement. Under terms of the Agreement, Marina Biotech will receive
an upfront payment plus milestone and royalty payments on products
developed by Tekmira that use UNA technology. Further terms of the
Agreement were not disclosed.  
"We are pleased to enter into this agreement with Tekmira, a leader
in the development of RNAi-based therapeutics," stated J. Michael
French, President and Chief Executive Officer of Marina Biotech.
"Marina Biotech's UNA technology is quite novel. Besides providing
drug-like properties to an RNAi drug, UNAs also eliminate passenger
strand activity as well as reduce guide strand mediated microRNA-like
off-target activity. The result is that UNAs are able to
significantly increase target specificity of an RNAi compound to its
gene target. We look forward to a continued relationship with the
great team at Tekmira." 
About Unlocked Nucleobase Analogs
 Unlocked Nucleobase Analogs (UNA)
are acyclic ribonucleoside analogs in which the bond between C2' and
C3' atoms is broken. This change in sugar structure renders this
nucleoside analog very flexible. This characteristic is in sharp
contrast to the widely used locked nucleosides that lock the sugar
conformation by a bridged bond between C2' and C4' atoms. The
flexible nature of UNA reduces the binding affinity between two
strands of an RNAi drug and gives unique characteristics to its genes
silencing abilities. Marina Biotech has demonstrated that UNA has the
potential to improve RNAi therapeutics by increasing stability and
reducing sense and antisense mediated off-target effects while
retaining potency. 
About Marina Biotech, Inc.
 Marina Biotech is a biotechnology company
focused on the development and commercialization of
oligonucleotide-based therapeutics utilizing multiple mechanisms of
action including RNA interference (RNAi) and messenger RNA
translational blocking. The Marina Biotech pipeline currently
includes a clinical program in Familial Adenomatous Polyposis (a
precancerous syndrome) and two preclinical programs -- in bladder
cancer and myotonic dystrophy. Marina Biotech has entered into an
agreement with both Mirna Therapeutics and ProNAi Therapeutics to
license Marina Biotech's SMARTICLES(R) technology for the delivery of
microRNA mimics and DNAi, respectively. In addition, Marina Biotech
announced exclusive licensing agreements with Monsanto Company for
Marina Biotech's delivery and chemistry technologies and with
Girindus America for the supply of CRN-based oligonucleotides. Marina
Biotech recently entered into a non-exclusive agreement with Novartis
Institutes for Biomedical Research to license Marina Biotech's CRN
technology for development of nucleic acid-based therapeutics. Marina
Biotech's goal is to improve human health through the development of
RNAi- and oligonucleotide-based compounds and drug delivery
technologies that together provide superior therapeutic options for
patients. Additional information about Marina Biotech is available at
http://www.marinabio.com. 
Forward-Looking Statements
 Statements made in this news release may
be forward-looking statements within the meaning of Federal
Securities laws that are subject to certain risks and uncertainties
and involve factors that may cause actual results to differ
materially from those projected or suggested. Factors that could
cause actual results to differ materially from those in
forward-looking statements include, but are not limited to: (i) the
ability of Marina Biotech to obtain additional and substantial
funding in the immediate future; (ii) the ability of Marina Biotech
to attract and/or maintain research, development, commercialization
and manufacturing partners; (iii) the ability of Marina Biotech
and/or a partner to successfully complete product research and
development, including preclinical and clinical studies and
commercialization; (iv) the ability of Marina Biotech and/or a
partner to obtain required governmental approvals; and (v) the
ability of Marina Biotech and/or a partner to develop and
commercialize products prior to, and that can compete favorably with
those of, competitors. Additional factors that could cause actual
results to differ materially from those projected or suggested in any
forward-looking statements are contained in Marina Biotech's most
recent periodic reports on Form 10-K and Form 10-Q that are filed
with the Securities and Exchange Commission. Marina Biotech assumes
no obligation to update and supplement forward-looking statements
because of subsequent events. 
Contact:
Michael French
Chief Executive Officer
(425) 892-4322
admin@marinabio.com